



REMARKS

In response to the NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES, applicants subjoin a sequence listing to the instant application. A computer readable sequence listing on 3.5 inch floppy diskette is enclosed as well. The sequence listing information recorded in computer readable form is identical to the written sequence listing. 37 CFR § 1.821(f).

The indicated portions of the specification have been supplemented with sequence identification numbers SEQ ID NO.1 – SEQ ID NO. 35 interposed after nucleotide sequences. 37 CFR § 1.821 (d). No new matter has been introduced. 37 CFR § 1.821(g).

If the Examiner believes a telephonic interview with Applicant's representative would aid in the prosecution of this application, he is cordially invited to contact Applicant's representative at the below listed number.

Pharmacia Corporation  
Corporate Patent Department O4E  
800 North Lindbergh Boulevard  
St. Louis, Missouri 63167

Respectfully submitted,

Philip B. Polster II  
Reg. No. 43,864  
(314) 694-9094  
(314) 694-9095 (facsimile)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Richardo Rocha et al.

Serial No. 09/916,136

Filed July 26, 2001

For: ALDOSTERONE BLOCKER THERAPY TO PREVENT OR TREAT  
INFLAMMATION-RELATED DISORDERS

Art Unit 1614

TECH CENTER 1600/2900

JUL 15 2002

RECEIVED

July 1, 2002

**AMENDMENT A – Version with Markings to show Changes Made**

COPY OF PAPERS  
ORIGINALLY FILED

IN THE SPECIFICATION

Page 110, first paragraph, lines 1-5, please deleted the indicated section and  
replace with:

***In situ Hybridization for Osteopontin mRNA***

RNA probes were generated based on a sequence for rat osteopontin (GenBank  
accession# NM 008608-1). Briefly, a cDNA fragment of rat osteopontin was generated  
by RT-PCR using the following primers: forward primer, 5'-TGG CAC ATT TGT CTT  
(SEQ ID NO. 1); reverse primer 3'AGC CCA TCC AGTC (SEQ ID NO. 2).

Page 111-112, Table 8 (Page 111, line 24-Page 112, lines 1-5), please delete  
Table 8 and replace with:

**Table 8            TaqMan RT-PCR Gene Marker Primer/Probe Sets**

Gene	Forward Primer	Reverse Primer	Probe
Transforming growth factor beta 1(TGFβ1)	CACCATCCATGA CATGAACC (SEQ. ID NO. 3)	ACCTTGCTGTACTG TGTGTCC (SEQ. ID NO.4)	TCAGCTCCACAG AGAAGAACTGC (SEQ. ID NO. 5)
Atrial natriuretic factor (ANP)	TGGGCTCCTTCTC CATCAC (SEQ. ID NO. 6)	AGCAGAGCCCTCA GTTTG (SEQ. ID NO. 7)	CCATATTGGAGC AAATCCCGTATA C (SEQ. ID NO. 8)
Collagen I	ACCAAGGCTGCA ACCTGGA (SEQ. ID NO. 9)	GCAGGAAGGTCAG CTGGAT (SEQ. ID NO. 10)	CCATACTCGAAC TGGAATCCATCG (SEQ. ID NO. 11)
Collagen III	GGCTTTCAGTTC AGCTATGG	GACTGTCTTGCTCC ATTCAC	CCTGATCTTCCTG AAGATGTCCTTG



	<b>(SEQ. ID NO. 12)</b> CTTGTCCATGGC AAATGCTG <b>(SEQ. ID NO. 15)</b>	<b>(SEQ. ID NO. 13)</b> GTGATCTTCTTGCT GGTCTTGC <b>(SEQ. ID NO. 16)</b>	<b>(SEQ. ID NO. 14)</b> CCACAATGCTCA TGCCTTCTTTCAC C <b>(SEQ. ID NO. 17)</b>
Cyclophilin			
Cyclooxygenase-2 (COX-2)	TCAAAGACACTC AGGTAGA CATGATCT <b>(SEQ. ID NO. 18)</b>	CGGCACCAGACCA AAGACTT <b>(SEQ. ID NO. 19)</b>	CACGTCCCTGAG CACCTGCGG <b>(SEQ. ID NO. 20)</b>
Osteopontin	CCAGCACACAAG CAGACGTT <b>(SEQ. ID NO. 21)</b>	TCAGTCCATAAGCC AAGCTATCAC <b>(SEQ. ID NO. 22)</b>	CAGTCGATGTCC CTGACGGCCG <b>(SEQ. ID NO. 23)</b>
Monocyte Chemoattractant Protein-1 (MCP-1)	GCAGGTCTCTGT CACGCTTCT <b>(SEQ. ID NO. 24)</b>	GGCTGAGACAGCA CGTGGAT <b>(SEQ. ID NO. 25)</b>	CCTGTTGTTCAC AGTTGCTGCCTG TAGC <b>(SEQ. ID NO. 26)</b>
Intercellular Adhesion Molecule-1 (ICAM-1)	ACCTGCAGCCGG AAAGC <b>(SEQ. ID NO. 27)</b>	CCCGTTTGACAGAC TTCACCAT <b>(SEQ. ID NO. 28)</b>	CCGATAGGCAGC GGGACACCA <b>(SEQ. ID NO. 29)</b>
Vascular Cell Adhesion Molecule - 1 (VCAM-1)	GAAGCCGGTCAT GGTCAAGT <b>(SEQ. ID NO. 30)</b>	GGTCACCCTTGAAC AGTTCTATCTC <b>(SEQ. ID NO. 31)</b>	TGGCTCCTGATG TTTACCCAATTG ACAGA <b>(SEQ. ID NO. 32)</b>
Cyclophilin	AGAGAAATTTGA GGATGAGAACTT CAT <b>(SEQ. ID NO. 33)</b>	TTGTGTTTGGTCCA GCATTTG <b>(SEQ. ID NO. 34)</b>	AAGCATACAGGT CCTGGCATCTTG TCCAT <b>(SEQ. ID NO. 35)</b>